This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Abi-Habib, R. J. Articles by Frankel, A. E. Search for Related Content PubMed PubMed Citation Articles by Abi-Habib, R. J. Articles by Frankel, A. E.

Systemic Anthrax Lethal Toxin Therapy Produces Regressions of Subcutaneous Human Melanoma Tumors in Athymic Nude Mice

Authors' Affiliations: ¹ Cancer Research Institute and ² Department of Pathology, Scott & White Memorial Hospital, Temple, Texas; ³ Bacterial Toxins and Therapeutics Section, National Institutes of Allergy and Infectious Diseases, Bethesda, Maryland; and ⁴ Van Andel Research Institute, Grand Rapids, Michigan

Requests for reprints: Arthur E. Frankel, Scott & White Memorial Hospital Cancer Research Institute, 5701 South Airport Road, Temple, TX 76502. Phone: 254-724-0094; Fax: 254-724-2324; E-mail: afrankel{at}swmail.sw.org.

Purpose: Anthrax Lethal Toxin (LeTx), composed of protective antigen and lethal factor, catalytically cleaves mitogen-activated protein kinase (MAPK) kinases and inhibits the MAPK signaling pathways. The majority of metastatic melanomas possess the V599E BRAF mutation, which constitutively activates MAPK1/2 signaling. LeTx is cytotoxic to BRAF mutant melanoma cell lines in vitro, whereas most normal cells are resistant to this toxin. In this study, we determine the in vivo potency and safety of systemically administered LeTx.

Experimental Design: A s.c. xenograft melanoma model in athymic nude mice was treated with different i.p. doses of LeTx.

Results: In this study, we show that in vivo systemic LeTx treatment of s.c. xenograft melanoma tumors in athymic nude mice yields partial and complete tumor regressions with minor toxicity to mice. When animal toxicity was observed, we did not find any histologic evidence of tissue damage.

Conclusions: LeTx is one of the rare targeted agents to produce complete remissions of human melanomas in an animal model and thus warrants further preclinical development.

This article has been cited by other articles:

				Y. Ding, E. A. Boguslawski, B. D. Berghuis, J. J. Young, Z. Zhang, K. Hardy, K. Furge, E. Kort, A. E. Frankel, R. V. Hay, et al. Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma Mol. Cancer Ther., March 1, 2008; 7(3): 648 - 658. [Abstract] [Full Text] [PDF]

				S. Liu, H. Wang, B. M. Currie, A. Molinolo, H. J. Leung, M. Moayeri, J. R. Basile, R. W. Alfano, J. S. Gutkind, A. E. Frankel, et al. Matrix Metalloproteinase-activated Anthrax Lethal Toxin Demonstrates High Potency in Targeting Tumor Vasculature J. Biol. Chem., January 4, 2008; 283(1): 529 - 540. [Abstract] [Full Text] [PDF]

				D. Huang, Y. Ding, W.-M. Luo, S. Bender, C.-N. Qian, E. Kort, Z.-F. Zhang, K. VandenBeldt, N. S. Duesbery, J. H. Resau, et al. Inhibition of MAPK Kinase Signaling Pathways Suppressed Renal Cell Carcinoma Growth and Angiogenesis In vivo Cancer Res., January 1, 2008; 68(1): 81 - 88. [Abstract] [Full Text] [PDF]

				P. Depeille, J. J. Young, E. A. Boguslawski, B. D. Berghuis, E. J. Kort, J. H. Resau, A. E. Frankel, and N. S. Duesbery Anthrax Lethal Toxin Inhibits Growth of and Vascular Endothelial Growth Factor Release from Endothelial Cells Expressing the Human Herpes Virus 8 Viral G Protein Coupled Receptor Clin. Cancer Res., October 1, 2007; 13(19): 5926 - 5934. [Abstract] [Full Text] [PDF]